TARHAPLI (registration number 5220451) is a United States trademark of DAIICHI SANKYO COMPANY, LIMITED. The goods and services are: Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, stroke, dyslipidemia, thrombosis, hyperphosphatemia, diabetes, cancer, oncological disease, leukemia, metastasis, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, osteoporosis, age-related macular degeneration, kidney disease The word “TARHAPLI” does not have any meaning in a foreign language. . The correspondent is Mark Lebow.
This trademark was filed on July 22, 2016 as United States Trademark Application Serial Number 79194599.
Trademark PTO Status
20220703 – NEW REPRESENTATIVE AT IB RECEIVED
20220613 – COURTESY REMINDER – SEC. 71 (6-YR) E-MAILED
20171028 – FINAL DECISION TRANSACTION PROCESSED BY IB
20170921 – FINAL DISPOSITION NOTICE SENT TO IB
20170921 – FINAL DISPOSITION PROCESSED
20170913 – FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
20170613 – REGISTERED-PRINCIPAL REGISTER
20170328 – OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Ownership History
DAIICHI SANKYO COMPANY, LIMITED
DAIICHI SANKYO COMPANY, LIMITED
DAIICHI SANKYO COMPANY, LIMITED
File a Trademark
Select IP monitors top trademarks which have been allowed and granted worldwide. We are experts in trademark law. If you are interested in connecting with an IP law attorney or patent law attorney, please contact us via the contact form.